X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs FRESENIUS KABI ONCO. - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA FRESENIUS KABI ONCO. CIPLA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 45.7 22.1 206.4% View Chart
P/BV x 3.9 3.1 125.8% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 CIPLA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    CIPLA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
CIPLA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs622176 353.4%   
Low Rs45879 583.8%   
Sales per share (Unadj.) Rs181.937.7 482.6%  
Earnings per share (Unadj.) Rs12.95.1 252.7%  
Cash flow per share (Unadj.) Rs29.36.7 436.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.742.5 365.9%  
Shares outstanding (eoy) m804.51158.23 508.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 88.0%   
Avg P/E ratio x42.025.0 168.0%  
P/CF ratio (eoy) x18.418.9 97.3%  
Price / Book Value ratio x3.53.0 116.0%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,51620,135 2,158.0%   
No. of employees `00023.01.2 2,000.3%   
Total wages/salary Rs m26,338703 3,745.5%   
Avg. sales/employee Rs Th6,349.15,176.2 122.7%   
Avg. wages/employee Rs Th1,143.0610.4 187.2%   
Avg. net profit/employee Rs Th449.3699.6 64.2%   
INCOME DATA
Net Sales Rs m146,3025,963 2,453.5%  
Other income Rs m2,28718 12,705.0%   
Total revenues Rs m148,5895,981 2,484.4%   
Gross profit Rs m24,7581,430 1,731.2%  
Depreciation Rs m13,229258 5,129.6%   
Interest Rs m1,594-26 -6,130.0%   
Profit before tax Rs m12,2221,216 1,004.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,798342 525.3%   
Profit after tax Rs m10,354806 1,284.8%  
Gross profit margin %16.924.0 70.6%  
Effective tax rate %14.728.1 52.3%   
Net profit margin %7.113.5 52.4%  
BALANCE SHEET DATA
Current assets Rs m87,3705,102 1,712.6%   
Current liabilities Rs m33,0812,385 1,386.8%   
Net working cap to sales %37.145.6 81.5%  
Current ratio x2.62.1 123.5%  
Inventory Days Days87150 58.0%  
Debtors Days Days62113 55.0%  
Net fixed assets Rs m111,5675,148 2,167.2%   
Share capital Rs m1,609158 1,017.1%   
"Free" reserves Rs m123,6456,556 1,886.1%   
Net worth Rs m125,2546,732 1,860.6%   
Long term debt Rs m36,454952 3,828.4%   
Total assets Rs m209,53210,388 2,017.1%  
Interest coverage x8.7-45.8 -18.9%   
Debt to equity ratio x0.30.1 205.8%  
Sales to assets ratio x0.70.6 121.6%   
Return on assets %5.77.5 76.0%  
Return on equity %8.312.0 69.1%  
Return on capital %8.514.6 58.2%  
Exports to sales %34.274.5 45.9%   
Imports to sales %8.324.8 33.7%   
Exports (fob) Rs m50,0504,441 1,127.1%   
Imports (cif) Rs m12,2031,477 826.0%   
Fx inflow Rs m51,0665,298 964.0%   
Fx outflow Rs m17,6781,772 997.5%   
Net fx Rs m33,3883,525 947.1%   
CASH FLOW
From Operations Rs m23,8241,274 1,869.8%  
From Investments Rs m-13,127-1,204 1,090.1%  
From Financial Activity Rs m-13,239-196 6,750.9%  
Net Cashflow Rs m-2,478-126 1,962.0%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 81.0 25.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 9.6 246.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 42,599 378.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS